ES2194495T3 - Agentes androgenos en combinacion con agentes gestagenos para la compensacion de una deficiencia de testosterona con proteccion de la prostata. - Google Patents
Agentes androgenos en combinacion con agentes gestagenos para la compensacion de una deficiencia de testosterona con proteccion de la prostata.Info
- Publication number
- ES2194495T3 ES2194495T3 ES99938132T ES99938132T ES2194495T3 ES 2194495 T3 ES2194495 T3 ES 2194495T3 ES 99938132 T ES99938132 T ES 99938132T ES 99938132 T ES99938132 T ES 99938132T ES 2194495 T3 ES2194495 T3 ES 2194495T3
- Authority
- ES
- Spain
- Prior art keywords
- agents
- combination
- prostate
- gestagen
- compensation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- 206010002261 Androgen deficiency Diseases 0.000 title abstract 2
- 239000003098 androgen Substances 0.000 title abstract 2
- 239000000583 progesterone congener Substances 0.000 title abstract 2
- 210000002307 prostate Anatomy 0.000 title 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 2
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 201000001514 prostate carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Utilización de un agente andrógeno natural o sintético en combinación con un componente seleccionado entre el grupo de los agentes gestágenos, para la preparación de una formulación en combinación destinada a la compensación de una deficiencia absoluta o relativa de testosterona con profilaxis simultánea para la génesis de una hiperplasia benigna de próstata (BPH) o de un carcinoma de próstata.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19825591A DE19825591A1 (de) | 1998-06-09 | 1998-06-09 | Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2194495T3 true ES2194495T3 (es) | 2003-11-16 |
Family
ID=7870308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES99938132T Expired - Lifetime ES2194495T3 (es) | 1998-06-09 | 1999-06-07 | Agentes androgenos en combinacion con agentes gestagenos para la compensacion de una deficiencia de testosterona con proteccion de la prostata. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20070078091A1 (es) |
EP (1) | EP1084569B1 (es) |
JP (1) | JP3645489B2 (es) |
AT (1) | ATE233976T1 (es) |
AU (1) | AU5277599A (es) |
CL (1) | CL2004000628A1 (es) |
DE (2) | DE19825591A1 (es) |
DK (1) | DK1084569T3 (es) |
ES (1) | ES2194495T3 (es) |
PT (1) | PT1084569E (es) |
WO (1) | WO1999065228A2 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003534375A (ja) * | 2000-05-26 | 2003-11-18 | フィッチ,ハリー | 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法 |
EP1210951B1 (en) * | 2000-11-30 | 2005-02-02 | Pfizer Products Inc. | Composition containing estrogen agonists/antagonists and testosterone for treating a decline in the level of the hormone testosterone |
US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
WO2005066195A1 (de) * | 2004-01-02 | 2005-07-21 | Pharmacon Forschung Und Beratung Gmbh | Verfahren zur herstellung von 1,2-ungesättigten azasteroiden |
US7138389B2 (en) | 2004-02-09 | 2006-11-21 | University Of Washington | Oral androgen therapy using modulators of testosterone bioavailability |
EP2305352A1 (en) * | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
EP2371367A1 (en) * | 2005-03-25 | 2011-10-05 | Merck Sharp & Dohme (I.A.) Corp. | Method of treating men with testosterone supplement and 5alpha reductase inhibitor |
CA2629244C (en) | 2005-11-11 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
EP1968705A1 (en) * | 2005-12-21 | 2008-09-17 | Pfizer Products Incorporated | Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor |
US20110092470A1 (en) * | 2006-03-21 | 2011-04-21 | Alan Meehan | Method of treating men with erectile dysfunction |
ES2385613T3 (es) | 2006-09-18 | 2012-07-27 | Boehringer Ingelheim International Gmbh | Método para tratar cánceres que portan mutaciones de EGFR |
JP5553767B2 (ja) * | 2008-11-07 | 2014-07-16 | 大日本住友製薬株式会社 | 新規で有用な下部尿路症状治療剤 |
EP2266567A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
EP2266568A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
WO2011003853A2 (en) | 2009-07-06 | 2011-01-13 | Boehringer Ingelheim International Gmbh | Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
WO2011082384A2 (en) | 2009-12-31 | 2011-07-07 | Differential Drug Development Associates, Llc | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
US20130303495A1 (en) * | 2009-12-31 | 2013-11-14 | Sov Therapeutics | Emulsion formulations |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
NZ631833A (en) | 2013-03-15 | 2017-06-30 | Differential Drug Dev Ass Llc | Emulsion formulations |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
US9744177B2 (en) | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
RU2018133932A (ru) | 2016-04-01 | 2020-05-12 | Терапьютиксмд, Инк. | Фармацевтическая композиция стероидного гормона |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
BE1028115B1 (fr) * | 2020-03-02 | 2021-09-27 | Georges Debled | Composition pour le traitement des cancers |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3423507A (en) * | 1966-02-25 | 1969-01-21 | Schering Corp | Method of treating benign prostratic hypertrophy |
DE2817157A1 (de) * | 1978-04-17 | 1979-10-25 | Schering Ag | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie |
DE3121152A1 (de) * | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie" |
US4704282A (en) * | 1984-06-29 | 1987-11-03 | Alza Corporation | Transdermal therapeutic system having improved delivery characteristics |
GB8506027D0 (en) * | 1985-03-08 | 1985-04-11 | Efamol Ltd | Pharmaceutical & dietary compositions |
US5059603A (en) * | 1989-06-12 | 1991-10-22 | Centuries Laboratories, Inc. | Method and composition for treating impotence |
IN171596B (es) * | 1989-06-27 | 1992-11-21 | Cohen Michael | |
ATE177949T1 (de) * | 1989-07-07 | 1999-04-15 | Endorecherche Inc | Kombinationstherapie zur prophylaxe und/oder behandlung benigner prostatahyperplasie |
DE4312034A1 (de) * | 1993-04-13 | 1994-10-20 | Hesch Rolf Dieter Prof Dr Med | Neuartige Androgene und Anabolika |
DE4318371A1 (de) * | 1993-05-28 | 1994-12-01 | Schering Ag | Mittel, enthaltend eine Verbindung mit antiandrogener sowie eine Verbindung mit kompetitiver, progesteronantagonistischer Wirkung |
ATE215826T1 (de) * | 1993-11-19 | 2002-04-15 | Jenapharm Gmbh | Karzinostatisches mittel für hormontherapie, das dienogest als wirksamer bestandteil enthält |
US5609617A (en) * | 1995-02-21 | 1997-03-11 | C. Norman Shealy | Method for enhancement of dehydroepiandrosterone |
US5599822A (en) * | 1995-06-06 | 1997-02-04 | Eli Lilly And Company | Methods for minimizing bone loss |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
WO1999046279A2 (en) * | 1998-03-11 | 1999-09-16 | Endorecherche, Inc. | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE |
-
1998
- 1998-06-09 DE DE19825591A patent/DE19825591A1/de not_active Withdrawn
-
1999
- 1999-06-07 AT AT99938132T patent/ATE233976T1/de not_active IP Right Cessation
- 1999-06-07 AU AU52775/99A patent/AU5277599A/en not_active Abandoned
- 1999-06-07 JP JP2000554127A patent/JP3645489B2/ja not_active Expired - Fee Related
- 1999-06-07 DK DK99938132T patent/DK1084569T3/da active
- 1999-06-07 DE DE59904462T patent/DE59904462D1/de not_active Expired - Fee Related
- 1999-06-07 ES ES99938132T patent/ES2194495T3/es not_active Expired - Lifetime
- 1999-06-07 WO PCT/DE1999/001652 patent/WO1999065228A2/de active IP Right Grant
- 1999-06-07 EP EP99938132A patent/EP1084569B1/de not_active Expired - Lifetime
- 1999-06-07 PT PT99938132T patent/PT1084569E/pt unknown
-
2004
- 2004-03-24 CL CL200400628A patent/CL2004000628A1/es unknown
-
2006
- 2006-09-08 US US11/517,301 patent/US20070078091A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU5277599A (en) | 1999-12-30 |
US20070078091A1 (en) | 2007-04-05 |
EP1084569B1 (de) | 2003-03-05 |
PT1084569E (pt) | 2003-07-31 |
DE19825591A1 (de) | 1999-12-23 |
WO1999065228A2 (de) | 1999-12-16 |
CL2004000628A1 (es) | 2005-01-07 |
ATE233976T1 (de) | 2003-03-15 |
JP3645489B2 (ja) | 2005-05-11 |
JP2002518294A (ja) | 2002-06-25 |
EP1084569A2 (de) | 2001-03-21 |
DK1084569T3 (da) | 2003-06-30 |
DE59904462D1 (de) | 2003-04-10 |
WO1999065228A3 (de) | 2000-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2194495T3 (es) | Agentes androgenos en combinacion con agentes gestagenos para la compensacion de una deficiencia de testosterona con proteccion de la prostata. | |
TR199900556T2 (xx) | Prostat hipertrofisini ve prostat kanserini tedavi etmek i�in vas�ta. | |
GEP20074122B (en) | Treating benign prostate hyperplasia with selective androgen receptor modulators | |
HUP9903732A3 (en) | Use of cgmp elevators for the preparation of pharmaceutical compositions treating benign prostatic hyperplasia | |
AR022803A1 (es) | Composiciones blanqueadoras estabilizadas | |
DK1556058T3 (da) | Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi | |
MXPA02005007A (es) | Uso de un antagonista h1 y un esteroide inocuo para tratar condiciones oculares. | |
TR200003377T2 (tr) | Estrojenler ile bütünleşik 2-fenil-1-[4-(2-aminoetoksi)benzil]-indol | |
BR0113670A (pt) | Composição farmacêutica e método para tratar hipogonadismo | |
TR199901604T2 (xx) | Tedavide yararl� kinolin ve kinazolin bile�ikleri. | |
AU1316000A (en) | Compositions and methods for treating benign prostatic hyperplasia using tocotrienols | |
CL2004000026A1 (es) | Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino. | |
AR039987A1 (es) | Utilizacion de inhibidores de la transduccion de senales inducida por egfr para el tratamiento de la hiperplasia de la prostata benigna (hpb)/hipertrofia de la prostata | |
AU3011299A (en) | Combination therapy for the treatment of benign prostatic hyperplasia | |
ECSP077247A (es) | Trans - clomifeno para el tratamiento de la hipertrofia prostatica benigna, cancer prostatico, hipogonodismo, trigliceridos elevados y alto colesterol | |
NZ508299A (en) | Testosterone derivative | |
BRPI0409950A (pt) | métodos e composições usando hormÈnio de liberação de hormÈnio gonadotropina | |
ATE225800T1 (de) | Nichtestrogene derivate des estradiols mit antioxidativer aktivität | |
WO2003024405A3 (en) | Methods and compositions for inhibiting the proliferation of prostate cancer cells | |
SE1212311T5 (es) | ||
DK0885005T3 (da) | Anvendelse af dehydroepiandrosteron og aromatasehæmmere til fremstilling af et lægemiddel til behandling af en relativ og absolut androgenmangel hos mænd | |
AR008778A1 (es) | Composiciones para el tenido por oxidacion de fibras queratinicas, procedimiento de tintura y dispositivo de tintura de varios compartimientos | |
MX9102021A (es) | Composiciones detergentes o blanqueadoras granuladas que contienen blanqueador de midoperoxiacido y perfume. | |
ES2175661T3 (es) | Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
CL2008000964A1 (es) | Composicion farmaceutica que comprende la combinacion sinergica de un inhibidor de la enzima 5 a-reductasa y un agente antagonista de los receptores a-adrenergicos, util para tratar la hiperplasia prostatica benigna. |